Assessment of a DNA-PK Inhibitor as a Chemo-potentiating Agent in Osteosarcoma

被引：0
|
作者：
O'Reilly, E. [1 ]
Vormoor, B. [1 ]
Kyle, S. [1 ]
Newell, H. [1 ]
机构：
[1] No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72087-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
289
引用
收藏
页码：88 / 89
页数：2
相关论文
共 50 条
  • [31] Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
    Munck, Joanne M.
    Batey, Michael A.
    Zhao, Yan
    Jenkins, Helen
    Richardson, Caroline J.
    Cano, Celine
    Tavecchio, Michele
    Barbeau, Jody
    Bardos, Julia
    Cornell, Liam
    Griffin, Roger J.
    Menear, Keith
    Slade, Andrew
    Thommes, Pia
    Martin, Niall M. B.
    Newell, David R.
    Smith, Graeme C. M.
    Curtin, Nicola J.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (08) : 1789 - 1798
  • [32] AZD7648: A potent and selective inhibitor of DNA-PK with pharmacodynamic and monotherapy anti-tumor activity
    Cadogan, Elaine B.
    Fok, Jacqueline H.
    Ramos-Montoya, Antonio
    James, Neil
    Follia, Valeria
    Vazquez-Chantada, Mercedes
    Winjhoven, Paul
    O'Connor, Lenka Oplustil
    Karmokar, Ankur
    Staniszewska, Anna
    Dean, Emma
    Hollingsworth, Simon J.
    Davies, Barry
    CANCER RESEARCH, 2019, 79 (13)
  • [33] A novel, selective inhibitor of DNA-dependent protein kinase (DNA-PK) potentiates the effects of DNA-damaging therapies in hepatocellular carcinoma
    Willoughby, Catherine E.
    Thomas, Huw D.
    Rennison, Tommy
    Cano, Celine
    Reeves, Helen L.
    Wedge, Stephen R.
    CANCER RESEARCH, 2017, 77
  • [34] Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
    Zenke, Frank T.
    Zimmermann, Astrid
    Sirrenberg, Christian
    Dahmen, Heike
    Kirkin, Vladimir
    Pehl, Ulrich
    Grombacher, Thomas
    Wilm, Claudia
    Fuchss, Thomas
    Amendt, Christiane
    Vassilev, Lyubomir T.
    Blaukat, Andree
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1091 - 1101
  • [35] A novel, selective DNA-PK inhibitor sensitizes poor prognosis chronic lymphocytic leukemia (CLL) cells to mitoxantrone
    Junge, Gesa
    CANCER RESEARCH, 2015, 75
  • [36] Chemosensitization of cancer cells by KU-0060648: A dual inhibitor of DNA-PK and PI-3K
    Batey, Michael A.
    Munck, Joanne M.
    Zhao, Yan
    Cano, Celine
    Tavecchio, Michele
    Bardos, Julia
    Griffin, Roger J.
    Jenkins, Helen
    Menear, Keith
    Smith, Graeme
    Thommes, Pia
    Newell, David R.
    Martin, Niall
    Curtin, Nicola J.
    CANCER RESEARCH, 2011, 71
  • [37] The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts
    Timme, Cindy R.
    Rath, Barbara H.
    O'Neill, Johnw.
    Camphausen, Kevin
    Tofilon, Philip J.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1207 - 1216
  • [38] The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
    Park H.J.
    Bae J.S.
    Kim K.M.
    Moon Y.J.
    Park S.-H.
    Ha S.H.
    Hussein U.K.
    Zhang Z.
    Park H.S.
    Park B.-H.
    Moon W.S.
    Kim J.R.
    Jang K.Y.
    Journal of Experimental & Clinical Cancer Research, 37 (1)
  • [39] The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
    Park, Hye Jeong
    Bae, Jun Sang
    Kim, Kyoung Min
    Moon, Young Jae
    Park, See-Hyoung
    Ha, Sang Hoon
    Hussein, Usama Khamis
    Zhang, Zhongkai
    Park, Ho Sung
    Park, Byung-Hyun
    Moon, Woo Sung
    Kim, Jung Ryul
    Jang, Kyu Yun
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [40] SY-7021, a novel DNA-PK inhibitor, exhibits significant anti-tumor activity in vitro and in vivo
    Zhang, Kai
    Liu, Zhihua
    Gao, Yuhao
    Lu, Chang
    Cheng, Shikang
    Liu, Xijie
    Luo, Hong
    Sun, Yinghui
    CANCER RESEARCH, 2024, 84 (06)
12345